Discovery and Characterization of Inhibitors of Ubiquitin-Like Modifier Activating Enzyme 5 (UBA5): Targeting the UFMylation Pathway in Cancer and Neurodegenerative Diseases
ACS Chemical Biology · 18.09.2026 · 21 (9) · 2200-2215
DOI: 10.1021/acschembio.6c00369 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Biology, online erschienen am 17.08.2026. Verfasst von Vigyasa Singh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, R Ken Coit College of Pharmacy, 1703 E Mabel St, Tucson, Arizona85721-0207, United States. Hauptthemen laut MEDLINE: Ubiquitin-Activating Enzymes, Neurodegenerative Diseases, Neoplasms, Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, Rainwater Charitable Foundation, University of Arizona College of Pharmacy faculty startup fund.
Abstract (Originalsprache)
UBA5 is the E1 enzyme that initiates UFMylation, a ubiquitin-like modification implicated in proteostasis, neurodegeneration, and cancer. Here, we report a chemical biology approach to interrogate UBA5 function through small-molecule inhibition. We developed a robust high-throughput screening assay based on AMP-GloTM and screened a library of blood–brain barrier-permeable compounds, identifying five inhibitors spanning three distinct scaffolds with low-micromolar potency. Orthogonal biochemical and gel-based assays confirmed that these compounds directly inhibit UBA5-mediated UFM1 activation and conjugation, with selectivity over other E1 enzymes, including UBA1. In cells, these compounds suppressed endogenous UFMylation without significantly affecting global polyubiquitination, supporting pathway and target engagement. Together, these studies establish UBA5 as a tractable enzymatic target and provide first-in-class chemical tools to probe UFMylation. Given the emerging role of UFMylation in disease, these inhibitors offer a foundation for developing therapeutics targeting proteostasis pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, R Ken Coit College of Pharmacy, 1703 E Mabel St, Tucson, Arizona85721-0207, United States.
- Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, New York10021, United States.
- The BIO5 Institute, The University of Arizona, Tucson, Arizona85721, United States.
- Biological Chemistry Program, Department of Chemistry and Biochemistry, College of Science & College of Medicine, The University of Arizona, Tucson, Arizona85721, United States.
- Department of Molecular & Cellular Biology, College of Science, The University of Arizona, Tucson, Arizona85721, United States.
ORCID-Profile: Yuansong Wan, Subhash Sinha, Hongmin Li
Förderung
- NIA NIH HHS
- Rainwater Charitable Foundation
- University of Arizona College of Pharmacy faculty startup fund
- Cure Alzheimer’s Fund
- R. Ken and Donna Coit Endowed Chair fund in Drug Discovery
- NIH
Zitieren
APA
Singh, V., Wan, Y., Gao, Z., Ahmed, T. R., Wang, S. Y., Chen, K., Kumar Samrat, S., Li, Z., Sinha, S., Gan, L., & Li, H. (2026). Discovery and Characterization of Inhibitors of Ubiquitin-Like Modifier Activating Enzyme 5 (UBA5): Targeting the UFMylation Pathway in Cancer and Neurodegenerative Diseases. ACS Chemical Biology, 21(9), 2200-2215. https://doi.org/10.1021/acschembio.6c00369
Vancouver
Singh V, Wan Y, Gao Z, Ahmed TR, Wang SY, Chen K, et al. Discovery and Characterization of Inhibitors of Ubiquitin-Like Modifier Activating Enzyme 5 (UBA5): Targeting the UFMylation Pathway in Cancer and Neurodegenerative Diseases. ACS Chemical Biology. 2026;21(9):2200-2215. doi:10.1021/acschembio.6c00369
BibTeX
@article{Singh2026,
author = {Singh, Vigyasa and Wan, Yuansong and Gao, Zhisong and Ahmed, Tahsin Reaz and Wang, Si-Yu and Chen, Ke and Kumar Samrat, Subodh and Li, Zhong and Sinha, Subhash and Gan, Li and Li, Hongmin},
title = {Discovery and Characterization of Inhibitors of Ubiquitin-Like Modifier Activating Enzyme 5 (UBA5): Targeting the UFMylation Pathway in Cancer and Neurodegenerative Diseases},
journal = {ACS Chemical Biology},
year = {2026},
volume = {21},
number = {9},
pages = {2200--2215},
doi = {10.1021/acschembio.6c00369}
}
EUVIMED